drugset / Trial / NCT03302351

Dexmedetomidine, Ketamine and Dexmetedomidine-Ketamine Combination for Control of Shivering During Regional Anaethesia

NCT03302351 ↗

Phase 4 Completed 94 enrolled Assiut University
RandomizedParallel-groupDouble-blindTreatment

Summary

Shivering is defined as an involuntary, repetitive activity of skeletal muscles. The incidence of shivering has been found to be quite high, approximately 40-50% in different studies. It can double or even triple oxygen consumption and carbon dioxide production. Shivering also increase intraocular and intracranial pressure, and may contribute to increased wound pain, delayed wound healing, and delayed discharge from post-anaesthetic care. Apart from being an uncomfortable experience, its deleterious effects deserve primary prevention and rapid control on occurence.

Timeline

Start
2017-10-01
Primary completion
2018-03-01
Completion
2018-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexmedetomidine Other / unclassified 0.5 ug/kg Intravenous
Subject Dexmedetomidine Other / unclassified 1 ug/kg Intravenous
Subject Ketamine Small molecule 0.25 mg/kg Intravenous
Subject Ketamine Small molecule 0.4 mg/kg Intravenous